Bievenue v. Takeda Pharmaceuticals USA, Inc. et al
Joyce Bievenue |
TAKEDA PHARMACEUTICALS U.S.A., INC, ASTRAZENECA LP, TAKEDA PHARMACEUTICAL COMPANY LIMITED, MERCK & CO INC, Takeda Development Center America Inc., ASTRAZENECA PHARMACEUTICALS LP and TAKEDA PHARMACEUTICALS AMERICA INC. |
PROTON-PUMP INHIBITOR PRODUCTS LIABILITY LITIGATION (No. II) |
2:2019cv16008 |
July 29, 2019 |
US District Court for the District of New Jersey |
Claire C Cecchi |
Mark Falk |
Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability |
28 U.S.C. § 1332 |
Both |
Docket Report
This docket was last retrieved on July 30, 2019. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 15 Clerk's Notice to Counsel. (jl, ) |
For all Case Management Orders #click here (jl, ) |
Member Case Direct File on 7/29/19 from the Northern District of Illinois 1:19-cv-4489 for MDL 2789 PROTON-PUMP INHIBITOR PRODUCTS LIABILITY LITIGATION (No. II) (jl, ) |
Judge Claire C. Cecchi and Chief Mag. Judge Mark Falk added. (jl, ) |
Filing 14 Certified Copy of Transfer Order and docket received, Case transferred in from District of Illinois Northern; Case Number 1:19-cv-04489. Original file certified copy of transfer order and docket sheet received. |
Filing 13 TRANSFERRED to the U.S.D.C. for the District of New Jersey the electronic record. (jjr, ) |
Filing 11 MINUTE entry before the Honorable Sharon Johnson Coleman: The presentment of defendants' motion to stay #8 is entered and continued. The presentment date of 7/24/2019 is stricken. Once the Judicial Panel on Multi-District Litigation finalized Conditional Transfer Order is entered transferring the case to the District of New Jersey, the Court will enter a final order. Mailed notice. (ym, ) |
Filing 12 CONDITIONAL TRANSFER ORDER from MDL Panel transferring case to U.S.D.C. for the District of New Jersey. Mailed notice. (jjr, ) |
***Civil Case Terminated pursuant to MDL 2789 Conditional Transfer Order filed 07/18/2019. (jjr, ) |
Filing 10 ANSWER to Complaint with Jury Demand by Takeda Development Center America Inc., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc.(Foster, Jennifer) |
Filing 9 NOTICE of Motion by Isaac J. Colunga for presentment of motion to stay #8 before Honorable Sharon Johnson Coleman on 7/24/2019 at 08:45 AM. (Colunga, Isaac) |
Filing 8 MOTION by Defendants Astrazeneca LP, Astrazeneca Pharmaceuticals LP, Merck & Co., Inc. to stay (Attachments: #1 Exhibit A, #2 Exhibit B)(Colunga, Isaac) |
Filing 7 MINUTE entry before the Honorable Sharon Johnson Coleman: This case has been assigned to the calendar of Judge Sharon Johnson Coleman and is set for a status hearing on 9/3/2019 at 9:00 AM. The parties are reminded to review the timelines set out in this Court's Standing Order Regarding the Mandatory Initial Discovery Pilot Project. The parties are directed to meet and discuss the status of the case. The parties are to file a joint status report in the format described on the court's website at www.ilnd.uscourts.gov at least 3 business days prior to the status. The parties are directed to discuss settlement, and whether they consent to proceed before the Magistrate Judge. The Court encourages the parties to review this court's website for its standing orders prior to contacting chambers. Mailed notice. (ym, ) |
Filing 6 ATTORNEY Appearance for Defendants Astrazeneca LP, Astrazeneca Pharmaceuticals LP, Merck & Co., Inc. by Heather Lynn Maly (Maly, Heather) |
Filing 5 NOTICE TO THE PARTIES - The Court is participating in the Mandatory Initial Discovery Pilot (MIDP). The key features and deadlines are set forth in this Notice which includes a link to the (MIDP) Standing Order and a Checklist for use by the parties. In cases subject to the pilot, all parties must respond to the mandatory initial discovery requests set forth in the Standing Order before initiating any further discovery in this case. Please note: The discovery obligations in the Standing Order supersede the disclosures required by Rule 26(a)(1). Any party seeking affirmative relief must serve a copy of the following documents (Notice of Mandatory Initial Discovery and the Standing Order) on each new party when the Complaint, Counterclaim, Crossclaim, or Third-Party Complaint is served. (mc, ) |
MAILED Notice of Removal letter to counsel of record. (mc, ) |
Filing 4 NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Merck & Co., Inc., D/B/A Merck, Sharp & Dohme Corporation (Colunga, Isaac) |
Filing 3 NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Astrazeneca LP, Astrazeneca Pharmaceuticals LP (Colunga, Isaac) |
Filing 2 ATTORNEY Appearance for Defendants Astrazeneca LP, Astrazeneca Pharmaceuticals LP, Merck & Co., Inc., D/B/A Merck, Sharp & Dohme Corporation by Isaac J. Colunga (Colunga, Isaac) |
Filing 1 NOTICE of Removal from Circuit Court of Cook County, Illinois, case number (2019L005949) filed by Astrazeneca LP, Astrazeneca Pharmaceuticals LP, Merck & Co., Inc., D/B/A Merck, Sharp & Dohme Corporation Filing fee $ 400, receipt number 0752-15993186. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Civil Cover Sheet Civil Cover Sheet)(Colunga, Isaac) |
CASE ASSIGNED to the Honorable Sharon Johnson Coleman. Designated as Magistrate Judge the Honorable Gabriel A. Fuentes. Case assignment: Random assignment. (ec, ) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the New Jersey District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.